STOCK TITAN
  1. Home
  2. News
  3. NAMSW

namsw - namsw STOCK NEWS

Welcome to our dedicated news page for namsw (Ticker: namsw), a resource for investors and traders seeking the latest updates and insights on namsw.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect namsw's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of namsw's position in the market.

News
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) has successfully achieved its enrollment target of 9,000 patients for the Phase 3 PREVAIL cardiovascular outcomes trial evaluating obicetrapib, a potential treatment for patients with cardiovascular disease. The company plans to extend enrollment to accommodate strong interest, with expectations to randomize over 9,000 patients by the end of April. Driven by the need for more effective therapies for patients with elevated LDL-C levels, NewAmsterdam aims to demonstrate obicetrapib's potential to reduce major adverse cardiac events and improve outcomes for those at risk of serious cardiovascular conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
clinical trial
-
News
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. appoints Juliette Audet as Chief Business Officer and announces her resignation from the Board of Directors. The company aims to develop oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
management
-
News
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) to present additional data from the Phase 2 ROSE2 clinical trial at the 2024 American College of Cardiology Congress. The trial evaluated obicetrapib in combination with ezetimibe for patients at risk of cardiovascular disease with elevated LDL-C. New data will show the impact on small dense LDL-C, a predictor of future cardiovascular events. NewAmsterdam also initiated the TANDEM Phase 3 trial for patients with HeFH and/or ASCVD. Details of the presentation include session title, date/time, location, and presentation title.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences clinical trial
News
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
Rhea-AI Summary
NewAmsterdam Pharma initiates TANDEM Phase 3 trial for obicetrapib and ezetimibe FDC in patients with high cholesterol levels and cardiovascular disease risk, aiming to improve LDL-C levels. The trial is expected to report topline data in Q1 2025, alongside BROOKLYN and BROADWAY studies. NewAmsterdam progresses with its Phase 3 trials, optimistic about the potential of their novel CETP inhibitor franchise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.89%
Tags
clinical trial
-
News
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces positive clinical trial progress, upcoming milestones, and financial results for 2023. They reported encouraging Phase 2 trial data for obicetrapib, with plans for Phase 3 trials and a pivotal trial for a fixed-dose combination. The company completed a successful public offering, raising $202 million. Despite a decrease in cash and revenue, R&D and SG&A expenses increased, resulting in a higher net loss for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
earnings
-
News
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announces participation in three upcoming investor conferences to present their late-stage, clinical biopharmaceutical developments for cardiovascular disease. Live webcasts and archived replays will be available for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
conferences
News
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces the pricing of a public offering, expecting to raise approximately $175.3 million to fund the development of oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
offering
-
News
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces a public offering of ordinary shares and pre-funded warrants. The underwritten public offering aims to raise capital for the late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
offering
-
News
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announced that CEO Michael Davidson and CFO Ian Somaiya will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The company is a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The webcast will be available through the investor relations section of the NewAmsterdam Pharma website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
conferences
News
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces the appointment of William H. Lewis, J.D., M.B.A., as Chair of its Board of Directors. Mr. Lewis brings over 30 years of executive experience in the pharmaceutical and finance industries, and is known for his commitment to advancing new therapies for serious and rare diseases. NewAmsterdam is looking forward to his contributions as they advance their CETP inhibitor toward market and work to deliver a simple, oral, once-daily option to millions of people living with dyslipidemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
management
Stock NAMSW logo
namsw

Nasdaq:NAMSW

NAMSW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NAMSW Stock Data

29.58M